NINTEDANIB

Brand name:

• Ofev®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Boehringer Ingelheim Pty Ltd

Condition/indication:
(therapeutic use)

• Progressive fibrosing interstitial lung disease (PF-ILD)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (Early Resolution Pathway)

Comment:

--

Other PBAC consideration:

• NINTEDANIB

Submission received for:

September 2021 PBAC meeting

Opportunity for consumer comment:

Open 23/12/2020 and close 10/02/2021 (see PBS Website)

PBAC meeting:

Held on 03/09/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

05/11/2021

Lodgement of required documentation:

15/11/2021

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 06/12/2021

Status:

Finalised

Government processes:

Commenced on 21/01/2022

Medicine listed on the PBS:

01/05/2022 (see PBS schedule)